CA3112382A1 - Methods for treating pancreatitis - Google Patents

Methods for treating pancreatitis Download PDF

Info

Publication number
CA3112382A1
CA3112382A1 CA3112382A CA3112382A CA3112382A1 CA 3112382 A1 CA3112382 A1 CA 3112382A1 CA 3112382 A CA3112382 A CA 3112382A CA 3112382 A CA3112382 A CA 3112382A CA 3112382 A1 CA3112382 A1 CA 3112382A1
Authority
CA
Canada
Prior art keywords
antibody
pancreatitis
functional fragment
seq
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112382A
Other languages
English (en)
French (fr)
Inventor
Dannielle D. ENGLE
David A. Tuveson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of CA3112382A1 publication Critical patent/CA3112382A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3112382A 2018-09-10 2019-09-09 Methods for treating pancreatitis Pending CA3112382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Publications (1)

Publication Number Publication Date
CA3112382A1 true CA3112382A1 (en) 2020-03-19

Family

ID=69776851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112382A Pending CA3112382A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis

Country Status (13)

Country Link
US (1) US12378320B2 (https=)
EP (1) EP3849605A4 (https=)
JP (1) JP7560445B2 (https=)
KR (1) KR20210073515A (https=)
CN (2) CN120267815A (https=)
AU (1) AU2019337564A1 (https=)
BR (1) BR112021004444A2 (https=)
CA (1) CA3112382A1 (https=)
CL (2) CL2021000585A1 (https=)
IL (1) IL281343A (https=)
MX (1) MX2021002761A (https=)
SG (1) SG11202102416SA (https=)
WO (1) WO2020055768A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277932A4 (en) * 2021-01-12 2024-06-12 Yeda Research and Development Co. Ltd Antibodies to cancer glycosylation and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US20250302409A1 (en) * 2024-03-26 2025-10-02 Hepatiq, Inc. Determining pancreas disease using functional imaging

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
AU2009279503B2 (en) * 2008-08-08 2014-05-29 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CA2918223A1 (en) 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277932A4 (en) * 2021-01-12 2024-06-12 Yeda Research and Development Co. Ltd Antibodies to cancer glycosylation and uses thereof

Also Published As

Publication number Publication date
JP2022500382A (ja) 2022-01-04
US20220049011A1 (en) 2022-02-17
CN113056286A (zh) 2021-06-29
AU2019337564A1 (en) 2021-05-06
CN113056286B (zh) 2025-04-29
IL281343A (en) 2021-04-29
CL2021000585A1 (es) 2021-08-13
JP7560445B2 (ja) 2024-10-02
CL2022000091A1 (es) 2022-11-18
CN120267815A (zh) 2025-07-08
US12378320B2 (en) 2025-08-05
EP3849605A4 (en) 2022-06-15
KR20210073515A (ko) 2021-06-18
BR112021004444A2 (pt) 2021-06-01
EP3849605A1 (en) 2021-07-21
MX2021002761A (es) 2021-05-31
WO2020055768A1 (en) 2020-03-19
SG11202102416SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
RU2707882C2 (ru) Нацеленное на gpc3 лекарственное средство, которое вводят пациенту, чувствительному к нацеленной на gpc3 лекарственной терапии
US9316654B2 (en) TAZ/WWTR1 for diagnosis and treatment of cancer
CN102421919B (zh) 采用Axl作为上皮‑间质转化的生物标志物的方法
US12378320B2 (en) Methods for treating pancreatitis
EP4034238B1 (en) Antibodies for the diagnosis and/or treatment of atherosclerosis
CN103238069B (zh) 肺癌和结直肠癌中的bard1同工型及其应用
CN106716132A (zh) 癌症的诊断
US10828377B2 (en) Method for determining presence or absence of suffering from malignant lymphoma or leukemia, and agent for treatment and/or prevention of leukemia
JP2019528437A (ja) 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
Qian et al. Involvement of USP7 in aggravating Kawasaki disease by promoting TGFβ2 signaling mediated endothelial-mesenchymal transition and coronary artery remodeling
WO2022154037A1 (ja) がんの予後バイオマーカー
Kozlova et al. A novel DNA repair protein, N-Myc downstream regulated gene 1 (NDRG1), links stromal tumour microenvironment to chemoresistance
WO2006064844A1 (ja) 大腸癌および／または大腸ポリープの診断ならびに術後経過観察および再発のモニター薬
US11739161B2 (en) Methods for treating and diagnosing prostate cancer
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
RU2839356C2 (ru) Способы лечения панкреатита
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
CN111656194B (zh) Tnbc划分和治疗的方法和组合物
US20240174765A1 (en) Anti- enolase 1 (eno1) antibody and applications thereof
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
WO2025217258A1 (en) Nptx1 antibodies
TW201818972A (zh) 針對ｍｅｌｋ的單株抗體及其用途
JP2023055804A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング
CN118086495A (zh) Sp1基因作为耐药实体瘤的生物标志物和治疗靶点的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240904

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260310